The $210 million PRV sale provides a significant non-dilutive cash infusion for a clinical-stage biotech. Monitor the HSR clearance timeline for closing. The cash strengthens the balance sheet and extends runway for pipeline programs.
Price Chart
Executive Summary
Ultragenyx entered into an asset purchase agreement on October 6, 2026 to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million in cash. The PRV was awarded by the FDA on August 19, 2026 upon approval of GENGLYCOS (DTX401) for glycogen storage disease type Ia. 20% of gross proceeds ($42 million) is payable to the NIH under a prior license agreement, leaving net proceeds of approximately $168 million.
Key Financial Metrics
Key Facts
- PRV sale price: $210 million in cash
- PRV awarded August 19, 2026 upon FDA approval of GENGLYCOS (DTX401)
- 20% of gross proceeds ($42 million) payable to NIH
- Net proceeds to Ultragenyx: approximately $168 million
- Transaction subject to HSR antitrust waiting period
- Closing conditions include customary representations, warranties, and indemnification
Financial Impact
$210 million gross cash inflow, ~$168 million net after NIH royalty
Risk Factors
- HSR antitrust review could delay or block closing
- NIH royalty reduces net proceeds by $42 million
- PRV sale is a one-time event with no recurring revenue
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-416251 |
| Document: 0001193125-26-416251-index.html | 0001193125-26-416251 |
| Document: 0001193125-26-416251.txt | 0001193125-26-416251 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | SC 13G | $15.92 | awaiting T+5 | — | $16.75 (+5.21%) |
Oct 19, 2026 8d ago | 8-K | $15.07 $16.08 | ▲ +6.70% | ▲ +6.85% | $16.75 (+11.15%) |
Oct 14, 2026 13d ago | 8-K | $14.90 $15.92 | ▲ +6.85% | ▲ +6.39% | $16.75 (+12.42%) |
Oct 7, 2026 20d ago | 8-K | $14.89 $14.90 | ▲ +0.07% | ▲ +1.05% | $16.75 (+12.49%) |
Sep 17, 2026 5w ago | Press Release | $14.50 $14.77 | ▲ +1.86% | ▲ +1.01% | $16.75 (+15.52%) |
Sep 2, 2026 7w ago | 8-K | $14.85 $14.30 | ▲ +3.70% | ▲ +2.56% | $16.75 (−12.79%) |
Sep 1, 2026 8w ago | Press Release | $26.53 $14.40 | ▼ −45.72% | ▼ −44.76% | $16.75 (−36.86%) |
Aug 11, 2026 11w ago | 8-K | $26.80 $25.49 | ▼ −4.89% | ▼ −4.48% | $16.75 (−37.50%) |
Aug 4, 2026 12w ago | 8-K | $24.93 $26.86 | ▲ +7.74% | ▲ +7.39% | $16.75 (−32.81%) |
Aug 4, 2026 12w ago | Insider Cluster | $25.81 $26.96 | ▲ +4.46% | ▲ +4.56% | $16.75 (−35.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers